# Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

> **NCT01680965** · PHASE1,PHASE2 · COMPLETED · sponsor: **H. Lee Moffitt Cancer Center and Research Institute** · enrollment: 44 (actual)

## Conditions studied

- Chronic Graft Versus Host Disease

## Interventions

- **DRUG:** Ofatumumab

## Key facts

- **NCT ID:** NCT01680965
- **Lead sponsor:** H. Lee Moffitt Cancer Center and Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-11-14
- **Primary completion:** 2020-08
- **Final completion:** 2020-08-30
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2022-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01680965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01680965, "Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01680965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*